Simcere Pharmaceutical (HKG:2096) said its Culevibart injection, branded Yingmule, received marketing approval from China's National Medical Products Administration.
The drug is indicated to prevent lower respiratory tract infections caused by respiratory syncytial virus in newborns and infants entering or born during their first RSV epidemic season, according to a Thursday filing.